|
|
 Previous Article | Table of Contents | Next Article 
Serum levels of interleukin-10 in patients with diffuse large cell
lymphoma: lack of correlation with prognosis [see comments]
JE Cortes, M Talpaz, F Cabanillas, JF Seymour and R Kurzrock
Department of Clinical Investigations, University of Texas MD Anderson
Cancer Center, Houston 77030, USA.
Interleukin-10 (IL-10), also known as cytokine synthesis inhibitory factor,
has multiple effects on lymphoid development. In addition, it has been
previously reported that serum levels of IL-10 correlate with failure-free
and overall survival in patients with non-Hodgkin's lymphoma. In this
study, we used a sensitive enzyme-linked immunosorbent assay specific for
human IL-10 (lower limit of sensitivity, 5 pg/mL) to measure serum levels
in 52 newly diagnosed patients with diffuse large cell lymphoma and at
least one adverse prognostic feature who were subsequently treated in a
uniform way. Lymphoma patients had significantly higher serum levels of
IL-10 (median, 7.98 pg/mL; range, < or = 5 to 27,143 pg/mL) than healthy
volunteers (N = 50; median, < or = 5 pg/mL; range, < or = 5 to 19.21
pg/mL) (P = .0000012). Individuals with B symptoms had significantly higher
serum levels of IL-10 than those without them (P = .03), but there was no
correlation between IL-10 levels and any of the other prognostic variables
analyzed, including age, lactic dehydrogenase, beta 2-microglobulin levels,
performance status, bulky disease, Ann Arbor stage, or International Index
score. More importantly, we found no correlation between IL-10 levels and
the achievement of complete remission, nor with failure-free survival or
overall survival. We conclude that in a uniform population of untreated
patients with diffuse large cell lymphoma, serum levels of IL-10 do not
appear to have any prognostic value.
Volume 85,
Issue 9,
pp. 2516-2520,
05/01/1995
Copyright © 1995 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
T. M. Habermann, S. S. Wang, M. J. Maurer, L. M. Morton, C. F. Lynch, S. M. Ansell, P. Hartge, R. K. Severson, N. Rothman, S. Davis, et al.
Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era
Blood,
October 1, 2008;
112(7):
2694 - 2702.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Asadullah, W. Sterry, and H. D. Volk
Interleukin-10 Therapy--Review of a New Approach
Pharmacol. Rev.,
June 1, 2003;
55(2):
241 - 269.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Fayad, M. J. Keating, J. M. Reuben, S. O'Brien, B.-N. Lee, S. Lerner, and R. Kurzrock
Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome
Blood,
January 1, 2001;
97(1):
256 - 263.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
